SCHEMBL6018451

SCHEMBL6018451

CN(C[C@H]1CC[C@H](OCCCCOS(C)(=O)=O)CC1)S(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.41
TAS2R14 Q9NYV8 1/20 0.41
HTR2C P28335 2/20 0.40
TP53 P04637 1/20 0.40
HTR2B P41595 1/20 0.40
ADRB2 P07550 1/20 0.38
POLB P06746 1/20 0.37
HTR2A P28223 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA3 P07451 1/20 0.35
CA4 P22748 1/20 0.35
CA6 P23280 1/20 0.35
CA5A P35218 1/20 0.35
CA7 P43166 1/20 0.35
CA9 Q16790 1/20 0.35
CA13 Q8N1Q1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6018986 1.00 LMNA (0.41) LMNATAS2R14HTR2CTP53HTR2B
SCHEMBL6018455 1.00 LMNA (0.41) LMNATAS2R14HTR2CTP53HTR2B
SCHEMBL6018802 0.88 LMNA (0.42) LMNATAS2R14HTR2CTP53HTR2B
SCHEMBL6018417 0.88 LMNA (0.42) LMNATAS2R14HTR2CTP53HTR2B
SCHEMBL6018421 0.88 LMNA (0.42) LMNATAS2R14HTR2CTP53HTR2B
SCHEMBL6019143 0.86 LSS (0.42) HTR2CHTR2BHTR2ALSSPSEN1
SCHEMBL6019141 0.86 LSS (0.42) HTR2CHTR2BHTR2ALSSPSEN1
SCHEMBL6019961 0.82 LSS (0.46) LMNATAS2R14HTR2CTP53HTR2B
SCHEMBL6019228 0.82 LSS (0.46) LMNATAS2R14HTR2CTP53HTR2B
SCHEMBL6019232 0.82 LSS (0.46) LMNATAS2R14HTR2CTP53HTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1456171-B1 SUBSTITUTED CYCLOHEXANE DERIVATIVES HOFFMANN LA ROCHE (CH) 2006-12-20 EP disclosed
US-20050272774-A1 Substituted cyclohexane derivatives ACKERMANN JEAN 2005-12-08 US disclosed
US-6953806-B2 Substituted cyclohexane derivatives HOFFMANN-LA ROCHE INC. (US) 2005-10-11 US disclosed
EP-1456171-A1 SUBSTITUTED CYCLOHEXANE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-09-15 EP disclosed
US-20030199550-A1 Substituted cyclohexane derivatives F.HOFFMANN-LA ROCHE AG (CH) 2003-10-23 US disclosed
WO-2003053919-A1 SUBSTITUTED CYCLOHEXANE DERIVATIVES F. HOFFMANN-LA-ROCHE AG (CH) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050272774-A1 Substituted cyclohexane derivatives LSS, CYP51A1, CYP8B1 LMNA 280/4885TAS2R14 4209/4885HTR2C 3745/4885
US-20030199550-A1 Substituted cyclohexane derivatives CYP51A1, LSS, CYP46A1 LMNA 485/4885TAS2R14 4172/4885HTR2C 3643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.